AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7066935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazemuls (lipid emulsion)
Number of subjects: 109
Study 7066935 — intervention group
Group type: COMPARATOR
Intervention: Valium
Number of subjects: 109
Study 30953552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained home visiting (MECSH)
Number of subjects: 41
Study 30953552 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 41
Study 28322414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n=100)
Number of subjects: 201
Study 28322414 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedation without dexmedetomidine; n=101)
Number of subjects: 201
Study 23672237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg orally twice daily for 24 weeks)
Number of subjects: 78
Study 23672237 — intervention group
Group type: COMPARATOR
Intervention: No cilostazol (Group A without claudication)
Number of subjects: 78
Study 23846810 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking group (standard care with feedback benchmarked against other centers)
Number of subjects: 4027
Study 23846810 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 4027
Study 23846810 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking group
Number of subjects: 4027
Study 23846810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4027
Study 21594960 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH(br) cells
Number of subjects: 21
Study 21594960 — intervention group
Group type: COMPARATOR
Intervention: ABMMNCs
Number of subjects: 21
Study 21594960 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study 18401699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 496
Study 18401699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 15968883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (640 microg ex‐actuator, equivalent to 800 microg ex‐valve, via hydrofluoroalkane metered‐dose inhaler)
Number of subjects: 18
Study 15968883 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg PO)
Number of subjects: 18
Study 15968883 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of ciclesonide and erythromycin
Number of subjects: 18
Study 12056936 — intervention group
Group type: EXPERIMENTAL
Intervention: Civamide (100 microL of 0.025% civamide, 25 microg) once daily for 7 days
Number of subjects: 28
Study 12056936 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (100 microL) once daily for 7 days
Number of subjects: 28
Study 10844404 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 197
Study 10844404 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 197
Study 10844404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 197
Study 8708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2
Number of subjects: 0
Study 8708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2
Number of subjects: 0
Study 8708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (both doses)
Number of subjects: 0
Study 8708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (high dose)
Number of subjects: 0
Study 8708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0
Study 1746996 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg BID
Number of subjects: 338
Study 1746996 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg HS
Number of subjects: 338
Study 1746996 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg HS and Famotidine 20 mg BID
Number of subjects: 338
Study 1746996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 6213641 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation (informative preoperative interview)
Number of subjects: 59
Study 6213641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (reassuring preoperative interview)
Number of subjects: 59
Study 6213641 — intervention group
Group type: COMPARATOR
Intervention: Control (no contact prior to surgery)
Number of subjects: 59
Study 30823947 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA (less invasive surfactant administration)
Number of subjects: 100
Study 30823947 — intervention group
Group type: COMPARATOR
Intervention: INSURE (INtubation SURfactant administration and Extubation)
Number of subjects: 100
Study 30823947 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA
Number of subjects: 100
Study 30823947 — intervention group
Group type: COMPARATOR
Intervention: INSURE
Number of subjects: 100
Study 27973989 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) plus Amoxicillin-Clavulanate (AC)
Number of subjects: 4
Study 27973989 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-Clavulanate (AC) alone
Number of subjects: 4
Study 27973989 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4
Study 27973989 — intervention group
Group type: COMPARATOR
Intervention: Saccharomyces boulardii (SB) alone
Number of subjects: 4
Study 26108607 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Number of subjects: 18
Study 23930929 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown rice (BR)
Number of subjects: 27
Study 23930929 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR)
Number of subjects: 27
Study 21494229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-reduced, low-fat diet (D)
Number of subjects: 439
Study 21494229 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity, facility-based aerobic exercise program (E)
Number of subjects: 439
Study 21494229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise (D+E)
Number of subjects: 439
Study 21494229 — intervention group
Group type: COMPARATOR
Intervention: No-lifestyle-change control (C)
Number of subjects: 439
Study 19466657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy or near-total thyroidectomy (group A)
Number of subjects: 346
Study 19466657 — intervention group
Group type: COMPARATOR
Intervention: Partial or subtotal thyroid gland removal treatment (group B)
Number of subjects: 346
Study 17224198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Swiss Francs incentive
Number of subjects: 44
Study 17224198 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Swiss Francs incentive
Number of subjects: 44
Study 17224198 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Swiss Francs incentive
Number of subjects: 44
Study 17224198 — intervention group
Group type: EXPERIMENTAL
Intervention: No reward
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laminectomy in cauda equina syndrome secondary to lumbar disc herniation
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy or microdiscectomy
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion surgery (probably non-instrumented)
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for discogenic pain
Number of subjects: 44
Study 15915304 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 44
Study 15915304 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapies
Number of subjects: 44
Study 12360380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal pethidine
Number of subjects: 100
Study 12360380 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 100
Study 9615847 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ketoprofen 100 mg i.v., 12 mg/h during surgery and for 48 hours afterwards
Number of subjects: 81
Study 9615847 — intervention group
Group type: COMPARATOR
Intervention: 100 mg ketoprofen as a bolus injection before the end of surgery, thereafter 12 mg/h ketoprofen continuously for 48 hours
Number of subjects: 81
Study 9615847 — intervention group
Group type: COMPARATOR
Intervention: Placebo during surgery and for 48 hours after surgery
Number of subjects: 81
Study 8714503 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg)
Number of subjects: 28
Study 8714503 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 28
Study 8714503 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 28
Study 2693686 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 73
Study 2693686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MF)
Number of subjects: 73
Study 2693686 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (low mindfulness) program
Number of subjects: 73
Study 2693686 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 73
Study 338092 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer technique of suture
Number of subjects: 137
Study 338092 — intervention group
Group type: COMPARATOR
Intervention: Two-layer technique of suture
Number of subjects: 137
Study 338092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of anastomotic leakage
Number of subjects: 137
Study 338092 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological examination for subclinical dehiscence
Number of subjects: 137
Study 31184670 — intervention group
Group type: EXPERIMENTAL
Intervention: Random patchy particles
Number of subjects: 0
Study 31184670 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous (isotropic) particles
Number of subjects: 0
Study 31184670 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous colloids
Number of subjects: 0
Study 25811297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Web-application for self-assessed symptoms reporting, with real-time data processing and alerts to oncologists.
Number of subjects: 98
Study 25811297 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (visit and imaging every 2 to 6 months).
Number of subjects: 98
Study 24832384 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 0
Study 24832384 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant
Number of subjects: 0
Study 23809454 — intervention group
Group type: EXPERIMENTAL
Intervention: All-inside ACL reconstruction
Number of subjects: 150
Study 23809454 — intervention group
Group type: COMPARATOR
Intervention: Full-tibial tunnel ACL reconstruction
Number of subjects: 150
Study 22104549 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing
Number of subjects: 121
Study 22104549 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 121
Study 19486449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg/day) for 28 days
Number of subjects: 60
Study 19486449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg o.d.) for 60 days
Number of subjects: 60
Study 15690650 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol palmitate (10,000 IU by mouth for 90 days)
Number of subjects: 19
Study 15690650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15690650 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol palmitate (after crossover from placebo)
Number of subjects: 19
Study 12088517 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin+oligofructose mixture
Number of subjects: 59
Study 12088517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 59
Study 12088517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 59
Study 9530125 — intervention group
Group type: EXPERIMENTAL
Intervention: daily exercise program (55% peak oxygen uptake)
Number of subjects: 19
Study 9530125 — intervention group
Group type: COMPARATOR
Intervention: sedentary life
Number of subjects: 19
Study 8556776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg daily for at least six months)
Number of subjects: 39
Study 8556776 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (500 mg daily for 30 days)
Number of subjects: 39
Study 8556776 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride supplementation (1 g daily for 30 days)
Number of subjects: 39
Study 8556776 — intervention group
Group type: COMPARATOR
Intervention: Control group (unmedicated normotensive men)
Number of subjects: 39
Study 2532922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (800 micrograms)
Number of subjects: 79
Study 2532922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 79
Study 2532922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propellant only)
Number of subjects: 79
Study 323705 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of estrogen
Number of subjects: 2680
Study 323705 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg of estrogen
Number of subjects: 2680
Study 323705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g of clofibrate
Number of subjects: 2680
Study 323705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2680
Study 31724878 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM (intermittently scanned continuous glucose monitoring)
Number of subjects: 59
Study 31724878 — intervention group
Group type: COMPARATOR
Intervention: SMBG (self‐monitoring of blood glucose)
Number of subjects: 59
Study 31724878 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 59
Study 28871620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant (1.5 mL of Curosurf) with sustained inflation manoeuvre (SIM)
Number of subjects: 19
Study 28871620 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 infants born before the study period)
Number of subjects: 19
Study 28871620 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 infants born after the study period)
Number of subjects: 19
Study 27919362 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3‐CA (omega‐3 carboxylic acids) 2, 3, or 4 g/d
Number of subjects: 399
Study 27919362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 399
Study 24534599 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy goals (aspirin use, blood pressure control, cholesterol levels, glucose levels, nonsmoking status, body mass index, exercise frequency)
Number of subjects: 3167
Study 22100903 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (per 5 kg/m(2) increase) for type 1 carcinomas
Number of subjects: 1070
Study 22100903 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (per 5 kg/m(2) increase) for type 2 carcinomas
Number of subjects: 1070
Study 20868963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PE (priming + ephedrine)
Number of subjects: 124
Study 20868963 — intervention group
Group type: COMPARATOR
Intervention: Group P (priming)
Number of subjects: 124
Study 20868963 — intervention group
Group type: COMPARATOR
Intervention: Group E (ephedrine)
Number of subjects: 124
Study 20868963 — intervention group
Group type: COMPARATOR
Intervention: Group NPE (no priming, no ephedrine)
Number of subjects: 124
Study 18378290 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (specific action plans for sunscreen use)
Number of subjects: 436
Study 18378290 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire-only control group
Number of subjects: 436
Study 15893104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention support group (RPSG)
Number of subjects: 291
Study 15893104 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized assessment and advice group (IAI)
Number of subjects: 291
Study 15893104 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group (DTC)
Number of subjects: 291
Study 12124484 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) measured by SPECT using the N‐isopropyl‐p‐[(123)I]iodoamphetamine autoradiography method
Number of subjects: 59
Study 12124484 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) measured by SPECT
Number of subjects: 59
Study 9650874 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with systemic metronidazole plus amoxicillin and supragingival irrigation with chlorhexidine digluconate
Number of subjects: 48
Study 9650874 — intervention group
Group type: COMPARATOR
Intervention: Full‐mouth scaling alone
Number of subjects: 48
Study 7662221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 28
Study 7662221 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg/day)
Number of subjects: 28
Study 2527541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 11
Study 2527541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 or 2.5 mg
Number of subjects: 11
Study 2527541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine and Cilazapril combined
Number of subjects: 11
Study 2527541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 824468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose penicillin (procaine penicillin G, 600,000 units intramuscularly, every 12 hours for up to ten days)
Number of subjects: 63
Study 824468 — intervention group
Group type: COMPARATOR
Intervention: High-dose penicillin (procaine penicillin G, same regimen as low-dose plus intravenous aqueous penicillin G, 10 million units daily for the first three days)
Number of subjects: 63
Study 824468 — intervention group
Group type: COMPARATOR
Intervention: High-dose penicillin
Number of subjects: 63
Study 824468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose penicillin
Number of subjects: 63
Study 824468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose penicillin and high-dose penicillin
Number of subjects: 63
Study 30706519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentors with visual impairment (VI)
Number of subjects: 0
Study 30706519 — intervention group
Group type: COMPARATOR
Intervention: Mentors without visual impairment (VI)
Number of subjects: 0
Study 28612547 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS + SC
Number of subjects: 33
Study 28612547 — intervention group
Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 33
Study 26424428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES) at 15/500/15,000 Hz, symmetrical rectangular biphasic current of 1-4 mAmp, 40 V for 20 min, 5 days per week for 3 weeks
Number of subjects: 30
Study 26424428 — intervention group
Group type: COMPARATOR
Intervention: Sham CES (device off) for 20 min, 5 days per week for 3 weeks
Number of subjects: 30
Study 26424428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 30
Study 23401601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg loading dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Number of subjects: 120
Study 23401601 — intervention group
Group type: COMPARATOR
Intervention: 20 mg fixed dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Number of subjects: 120
Study 23401601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (loading-dose and fixed-dose)
Number of subjects: 120
Study 21475137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet with carbohydrates eaten mostly at dinner
Number of subjects: 78
Study 19419359 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with bupivacaine 15 mg, 0.15 mg of intrathecal morphine and 15 microg of fentanyl
Number of subjects: 40
Study 19419359 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with sufentanil
Number of subjects: 40
Study 19419359 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 40
Study 19419359 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 40
Study 17724395 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with weighted vests (3 sessions per week for 12 weeks, vest load up to 15% of body weight)
Number of subjects: 16
Study 17724395 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with weighted vests
Number of subjects: 16
Study 17724395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 16
Study 14998850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin alone (OXA)
Number of subjects: 63
Study 14998850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with infusional 5-FU (OXFU)
Number of subjects: 63
Study 14998850 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU alone (5-FU)
Number of subjects: 63
Study 11800513 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interventions (theory of gender and power, social learning theory, cognitive behavioral theory)
Number of subjects: 445
Study 11800513 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 445
Study 11800513 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interventions
Number of subjects: 445
Study 9555617 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + Ipratropium (100 micrograms/inh salbutamol + 20 micrograms/inh ipratropium)
Number of subjects: 120
Study 9555617 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 micrograms/inh)
Number of subjects: 120
Study 9555617 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (20 micrograms/inh)
Number of subjects: 120
Study 9555617 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + Ipratropium
Number of subjects: 120